Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04:42 | Sharp Therapeutics Corp (2): Sharp Therapeutics shareholders approve AGM resolutions | 2 | Stockwatch | ||
Mo | Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 210 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small... ► Artikel lesen | |
22.05. | Sharp Therapeutics Corp. Reports First Quarter 2025 Results | 302 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
14.05. | Sharp Therapeutics Corp (2): Sharp nominates clinical candidate for Gaucher's | 1 | Stockwatch | ||
13.05. | Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease | 318 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
21.04. | Sharp Therapeutics Corp (2): Sharp receives $2.5M (U.S.) from warrant exercise | 2 | Stockwatch | ||
21.04. | STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp. | 309 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
27.01. | Sharp Therapeutics Corp (2): Sharp Therapeutics completes 1:10 rollback | 1 | Stockwatch | ||
27.01. | Sharp Therapeutics Corp. Completes Share Consolidation | 347 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
16.01. | Sharp Therapeutics Corp. Announces Share Consolidation | 268 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
12.12.24 | Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction | 305 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Sharp Therapeutics Corp. (TSXV: EVP.P) ("Sharp Therapeutics"), formerly EVP Capital Inc. ("EVP Capital"), an Ontario corporation is pleased... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
EVOTEC | 6,156 | -17,44 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,040 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,340 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics: Oppenheimer erhöht Kursziel auf 14 US-Dollar | ||
REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets | PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector... ► Artikel lesen | |
ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
ADMA BIOLOGICS | 17,130 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
QIAGEN | 40,855 | -0,48 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
HARMONY BIOSCIENCES | 35,210 | 0,00 % | Truist Securities initiates Harmony Biosciences stock with Buy rating | ||
KYMERA THERAPEUTICS | 45,140 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
VERVE THERAPEUTICS | 10,955 | 0,00 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |